Kringle Pharma, Inc. (JP:4884)
:4884
Top Page
Kringle Pharma, Inc.
(4884)
Select Model
Select Model
Rating:50Neutral
Price Target:
¥448.00
▲(18.21% Upside)
Action:ReiteratedDate:04/07/26
The score is held back primarily by weak financial performance (large losses, declining recent revenue, and ongoing cash burn), only partly offset by a debt-free balance sheet. Technicals are supportive in the near term but look overbought, while valuation offers limited support due to unprofitability and no dividend yield data.
Positive Factors
Proprietary HGF platform
Kringle's proprietary HGF platform is a durable, platform-level competitive advantage that can support multiple indications (SCI, ALS, inflammatory conditions). A platform enables pipeline breadth, repeatable R&D processes and greater licensing or partner appeal over the medium term.
Negative Factors
Structural unprofitability
Persistent, large operating and net losses erode equity and limit internal reinvestment. Structural unprofitability increases dependence on external capital, pressures R&D pacing, and can constrain long-term program continuity if funding becomes scarce.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary HGF platform
Kringle's proprietary HGF platform is a durable, platform-level competitive advantage that can support multiple indications (SCI, ALS, inflammatory conditions). A platform enables pipeline breadth, repeatable R&D processes and greater licensing or partner appeal over the medium term.
Read all positive factors
Kringle Pharma, Inc. (4884) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥3.75B
Dividend YieldN/A
Average Volume (3M)51.60K
Price to Earnings (P/E)―
Beta (1Y)0.75
Revenue Growth-9.77%
EPS Growth-13.86%
CountryJP
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-28.20
Shares Outstanding8,078,200
10 Day Avg. Volume53,170
30 Day Avg. Volume51,600
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)2.41
Price to Sales (P/S)43.77
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kringle Pharma, Inc. Business Overview & Revenue Model
Company Description
Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines. The company develops HGF products for the treatment of acute spinal cord injur...
How the Company Makes Money
Kringle Pharma, Inc. generates revenue primarily through funding from research grants, partnerships, and licensing agreements with other pharmaceutical and biotech companies. It monetizes its proprietary HGF technology by developing drug candidate...
Kringle Pharma, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
20
Very Negative
| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 72.22M | 80.04M | 69.25M | 391.83M | 289.76M |
| Gross Profit | 72.22M | 0.00 | 0.00 | 303.42M | 218.16M |
| EBITDA | -909.45M | -817.88M | -888.76M | -426.17M | -357.88M |
| Net Income | -916.25M | -756.45M | -854.15M | -331.83M | -301.17M |
Balance Sheet | |||||
| Total Assets | 2.08B | 2.76B | 2.62B | 3.21B | 2.64B |
| Cash, Cash Equivalents and Short-Term Investments | 1.62B | 2.31B | 2.14B | 2.76B | 2.14B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 770.11M | 648.92M | 596.95M | 419.50M | 129.48M |
| Stockholders Equity | 1.31B | 2.11B | 2.02B | 2.79B | 2.51B |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -661.17M | -689.10M | 15.80M | -560.92M |
| Operating Cash Flow | -755.78M | -661.17M | -689.10M | 15.80M | -560.92M |
| Investing Cash Flow | -154.01M | -121.36M | -120.88M | -254.38M | 0.00 |
| Financing Cash Flow | 84.14M | 838.23M | 69.16M | 603.11M | 595.90M |
Kringle Pharma, Inc. Technical Analysis
Positive
379.00
Price Trends
400.00
Positive
400.62
Positive
488.31
Negative
Market Momentum
19.29
Negative
56.44
Neutral
31.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4884, the sentiment is Positive. The current price of 379 is below the 20-day moving average (MA) of 417.10, below the 50-day MA of 400.00, and below the 200-day MA of 488.31, indicating a neutral trend. The MACD of 19.29 indicates Negative momentum. The RSI at 56.44 is Neutral, neither overbought nor oversold. The STOCH value of 31.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4884.
Kringle Pharma, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | ¥11.15B | -12.44 | -26.70% | ― | 172.39% | 8.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥3.75B | -3.45 | ― | ― | -9.77% | -13.86% | |
47 Neutral | ¥4.78B | -4.17 | ― | ― | -100.00% | 7.60% | |
46 Neutral | ¥159.56B | -57.13 | -10.16% | ― | -62.47% | -134.06% | |
42 Neutral | ¥3.59B | -1.20 | ― | ― | -16.23% | -51.84% | |
41 Neutral | ¥2.53B | -3.79 | ― | ― | ― | 25.25% |
* Healthcare Sector Average
JP:4884
Kringle Pharma, Inc.
464.00
-320.00
-40.82%
JP:4587
Peptidream
1,229.00
-654.00
-34.73%
JP:4571
NanoCarrier Co., Ltd.
148.00
23.00
18.40%
JP:4591
Ribomic, Inc.
88.00
3.00
3.53%
JP:4598
Delta-Fly Pharma, Inc.
192.00
-287.00
-59.92%
JP:4881
FunPep Company Limited
80.00
-19.00
-19.19%
Kringle Pharma, Inc. Corporate Events
Kringle Pharma Posts Narrower Quarterly Loss but Confirms Deep Full-Year Deficit Forecast
Feb 9, 2026
Kringle Pharma reported net sales of ¥18 million for the three months ended December 31, 2025, flat year on year, while operating and ordinary losses narrowed slightly to around ¥199–¥200 million, resulting in a quarterly net ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.